ERBB2 and breast carcinoma: Almost 80% of breast cancer patients belong to the Luminal A (ER+ and/or PR+, HER2−) and Luminal B (ER+ and/or PR+, HER2+) subgroups, which highlight the major role of the hormonal receptors in this disease [5].